نتایج جستجو برای: sustained virologic response

تعداد نتایج: 1043902  

2014
Nobuhiro Harada Sumihito Tamura Yasuhiko Sugawara Junichi Togashi Takeaki Ishizawa Junichi Kaneko Taku Aoki Yoshihiro Sakamoto Kiyoshi Hasegawa Tomohiro Tanaka Noriyo Yamashiki Norihiro Kokudo

Single nucleotide polymorphisms of interleukin-28B (IL28B) rs8099917 are reported to be associated with virologic clearance in interferon-and ribavirin -based treatment for hepatitis C virus (HCV)-infected patients. We examined virologic response in accordance with IL28B polymorphisms in our living donor liver transplantation series under a preemptive interferon and RBV treatment approach. Adeq...

2013
Ahmet Uyanikoglu Sabahattin Kaymakoglu Ahmet Danalioglu Filiz Akyuz Fatih Ermis Binnur Pinarbasi Kadir Demir Fatih Besisik Yilmaz Cakaloglu

BACKGROUND/AIMS The aim of this study is to investigate the rate of sustained virologic response (SVR) in chronic hepatitis C patients receiving antiviral treatment. METHODS The files of patients with chronic hepatitis C treated with interferon±ribavirin between 1995 and 2009 were reviewed retrospectively. Six months after the end of treatment, patients with negative hepatitis C virus (HCV)-R...

Journal: :The New England journal of medicine 2013
Eric Lawitz Edward J Gane

BACKGROUND In phase 2 trials, the nucleotide polymerase inhibitor sofosbuvir was effective in previously untreated patients with chronic hepatitis C virus (HCV) genotype 1, 2, or 3 infection. METHODS We conducted two phase 3 studies in previously untreated patients with HCV infection. In a single-group, open-label study, we administered a 12-week regimen of sofosbuvir plus peginterferon alfa-...

2012
Yoshihiro Kawamura Shigeru Takasaki Masashi Mizokami

The recommended treatment for patients with chronic hepatitis C, pegylated interferon α (PEG-IFN-α) plus rebavirin (RBV), does not provide a sustained virologic response in all patients, especially those with hepatitis C virus (HCV) genotype 1. It is therefore important to predict whether or not a new patient with HCV genotype 1 will be cured by the recommended treatment. We propose a predictio...

Journal: :hepatitis monthly 0
ioan sporea department of gastroenterology and hepatology, university of medicine and pharmacy, romania +40-256309455, [email protected]; department of gastroenterology and hepatology, university of medicine and pharmacy, romania +40-256309455, [email protected] alina popescu department of gastroenterology and hepatology, university of medicine and pharmacy, romania manuela curescu department of gastroenterology and hepatology, university of medicine and pharmacy, romania roxana sirli department of gastroenterology and hepatology, university of medicine and pharmacy, romania isabel dan department of gastroenterology and hepatology, university of medicine and pharmacy, romania adrian goldis department of gastroenterology and hepatology, university of medicine and pharmacy, romania

Journal: :ACP journal club 2002
Paul D King

S t u d y s e l e c t i o n Studies in any language were selected if they were randomized controlled trials that compared interferon with placebo or no treatment; examined patients with acute HCV infection; and included ≥ 1 of normalization of alanine aminotransferase (ALT) activity at the end of treatment (biochemical end treatment response [ETR]), sustained ALT normalization at the end of fol...

Journal: :International Journal of Medical Sciences 2006
Steven K. Herrine Victor J. Navarro

Despite the improved efficacy of peginterferons, the rate of sustained virologic response is suboptimal in cirrhotic patients, relative to non-cirrhotic patients. However, the treatment of patients with compensated cirrhosis has recently been encouraged by expert panels. Interferon-based therapy may provide additional benefit by reducing the risk of hepatocellular carcinoma in cirrhotic patient...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید